Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 125.04 +0.58 (0.47%)
price chart
Johnson & Johnson to phase out potentially harmful chemicals by 2015
(CBS/AP) Johnson & Johnson says it will remove carcinogenic chemicals and other potentially harmful substances from nearly all its adult toiletries and cosmetic products worldwide within 3.5 years.
Johnson & Johnson to Remove Formaldehyde From Products  New York Times
Johnson & Johnson removing harsh chemicals from products by 2015  Fox News
Johnson & Johnson Announces a Ban on Harmful Chemicals in Products
Johnson & Johnson made the landmark announcement this week that it would ban harmful chemicals from their products. The company has already made the pledge to remove toxic chemicals from its baby products by 2013.
Globe trotter: Johnson & Johnson comes clean  Economic Times
The Real Lesson of Formaldehyde In Baby Shampoo  TIME
Berkshire Cuts Johnson & Johnson Stake
Berkshire Hathaway Inc. added a stake in National Oilwell Varco Inc. in the second quarter as billionaire Chairman Warren Buffett pared investments in consumer-products stocks including Procter & Gamble Co.
Buffett's Berkshire cuts stakes in J&J, Kraft, P&G  MarketWatch
Warren Buffett's Berkshire Hathaway Drops Intel, Bets On Oil  International Business Times
Johnson & Johnson unit recalls bone putty
REUTERS/Christian Hartmann. The health regulator said certain lots of bone putty made by Johnson & Johnson unit Synthes were recalled as there was potential for the putty to catch fire if it came in contact with electrosurgical cautery systems during ...
Synthes Bone Putty Recalled Over Fire Risk During Surgery  Law360 (subscription)
Johnson & Johnson makes $50 million milestone payment to California-based ...
Janssen Biotech, part of Johnson & Johnson, will pay a $50 million milestone payment to Pharmacyclics, its collaborator on a new treatment for mantle cell lymphoma.
Johnson & Johnson Unit Settles State Cases Over Risperdal
Johnson & Johnson announced Thursday that its pharmaceutical unit had reached a $181 million consumer fraud settlement with 36 states and the District of Columbia over its marketing of Risperdal, an antipsychotic drug.
Johnson & Johnson to Pay $181M Settlement Over Risperdal Marketing  Becker's Hospital Review
Here Are The Allegations That Spurred J&J To Pay A $181 Million ...  Business Insider
JNJ is under federal investigation for marketing practices of a drug and device
In its latest quarterly earnings report filed with the U.S. Securities and Exchange Commission last week, Johnson and Johnson disclosed that the company is under federal investigation for marketing practices related to two products - a drug and a ...
No More Tears: Johnson & Johnson Cleans Up Its Act and Removes Carcinogens
Prompted by growing concerns raised by the Campaign for Safe Cosmetics, Johnson & Johnson makers of Aveeno, Neutrogena, and Johnson's Baby Shampoo, announced today that it will be removing carcinogens and other toxic chemicals from its baby ...
Related articles »  
Johnson & Johnson Eyes China's Baby Market
Johnson & Johnson is rumored to be considering the acquisition of a local baby-care product vendor Shanghai Elsker in China, a move that could strengthen its foothold in the rapidly-growing Chinese baby-care market.
Genmab, Johnson & Johnson agree $1.1 billion cancer deal
Janssen Biotech will make an upfront payment of $55 million for the license and Johnson & Johnson Development Corp would invest 475 million Danish crowns ($80 million) in new Genmab shares, the company said.
J&J grabs Genmab's promising leukemia antibody in $1.1B deal  FierceBiotech